Identifying key clinical and biochemical predictors of treatment outcomes in inflammatory bowel disease: a real-world evidence study
Open Access
- 21 November 2025
- journal article
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 41350
Abstract
Inflammatory bowel disease (IBD), including Crohn's disease and Ulcerative colitis, often shows variable responses to biological therapies. Identifying the most significant variables for predicting the response to these therapies could help prioritize efforts in data collection and preprocessing. This study evaluated the predictive performance of machine learning models in forecasting remission and response to vedolizumab and ustekinumab in the treatment of IBD. The goal was not to compare the two therapies, but rather to identify the variables most influential in predicting response for each treatment. Data from 227 IBD patients treated at Virgen Macarena University Hospital (2015-2022) were analyzed. Clinical, demographic, and laboratory variables were used to develop Extreme gradient boosting (XGBoost) models to predict the clinical response at 26 and 52 weeks and remission at 52 weeks. Model performance was evaluated via F1 scores, accuracy, precision, and recall, with fairness analyses across sex and age groups. The models achieved F1 scores of 0.842, 0.869, and 0.649, respectively. The predictors included leukocyte count, FCP, CRP, and vitamin B12 levels, with higher inflammatory marker levels linked to poorer responses. Demographic subgroup analysis revealed variability in model performance due to small sample sizes. Machine learning models have potential as clinical decision support tools for personalizing IBD treatment. These findings underscore the value of leveraging real-world evidence in optimizing therapeutic strategies. Further multicenter studies are needed to validate these models and enhance their applicability across diverse populations. Taken together, these findings arise from an exploratory, hypothesis-generating study that constitutes an early step toward truly personalized biologic therapy in IBD.Keywords
Funding Information
- EU-NextGenerationEU and the Recovery, Transformation, and Resilience Plan, granted to the Ministry of Employment, Training, and Autonomous Work (SE/INV/0008/2022, SE/INV/0008/2022, SE/INV/0008/2022, SE/INV/0008/2022, SE/INV/0008/2022)
- Sociedad Andaluza de Patología Digestiva through the Beca del Grupo Andaluz de Trabajo de Enfermedad Inflamatoria Intestinal 2022
- Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa
This publication has 24 references indexed in Scilit:
- Artificial Intelligence for Inflammatory Bowel Diseases (IBD); Accurately Predicting Adverse Outcomes Using Machine LearningDigestive Diseases and Sciences, 2022
- Machine Learning-based Prediction Models for Diagnosis and Prognosis in Inflammatory Bowel Diseases: A Systematic ReviewJournal of Crohn's and Colitis, 2021
- Machine learning using clinical data at baseline predicts the efficacy of vedolizumab at week 22 in patients with ulcerative colitisScientific Reports, 2021
- Pathophysiology of Inflammatory Bowel DiseasesNew England Journal of Medicine, 2020
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 VaccineNew England Journal of Medicine, 2020
- Development and Validation of Machine Learning Models in Prediction of Remission in Patients With Moderate to Severe Crohn DiseaseJAMA Network Open, 2019
- Implementing Machine Learning in Health Care — Addressing Ethical ChallengesNew England Journal of Medicine, 2018
- Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel DiseaseClinical Gastroenterology and Hepatology, 2016
- Phenotypic Features of Crohn's Disease Associated With Failure of Medical TreatmentClinical Gastroenterology and Hepatology, 2014
- Assessing Response and Loss of Response to Biological Therapies in IBDAmerican Journal of Gastroenterology, 2011